Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216220 | 0.84 | GPR119 (0.39) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2216225 | 0.84 | GPR119 (0.39) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2215227 | 0.84 | GPR119 (0.40) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2370710 | 0.83 | GPR119 (0.45) | GPR119GPR183NR1H4 | |
| SCHEMBL2218508 | 0.83 | GPR119 (0.39) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL2216969 | 0.81 | GPR119 (0.40) | GPR119GPR183MEN1 | |
| SCHEMBL2214982 | 0.80 | GPR119 (0.41) | GPR119GPR183 | |
| SCHEMBL1854120 | 0.79 | GPR119 (0.45) | GPR119 | |
| SCHEMBL2215285 | 0.78 | GPR119 (0.39) | GPR119GPR183MEN1CYP3A4 | |
| SCHEMBL1295590 | 0.77 | GPR119 (0.55) | GPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885GPR183 27/4885NR1H4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.